Drugs /

ace1702

Back to Drugs List

Overview

NCI Definition [1]:
An off-the-shelf preparation of natural killer (NK) cells conjugated to a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), with potential antineoplastic activity. Upon administration of anti-HER2 antibody conjugated natural killer cells ACE1702, the antibody moiety targets and binds to HER2 on tumor cells, which may lead to cell lysis of HER2-expressing tumor cells by the NK cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.

Clinical Trials

View Clinical Trials for ace1702

Ace1702 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating ace1702, 1 is phase 1 (1 open).

ERBB2 Amplification, HER2 Overexpression, and HER2 Positive are the most frequent biomarker inclusion criteria for ace1702 clinical trials.

Malignant solid tumor is the most common disease being investigated in ace1702 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Ace1702
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ace1702 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
anti-her2 antibody conjugated nk cells ace1702, anti-her2 onk cells, ace 1702, anti-her2 antibody conjugated natural killer cells ace1702
Drug Target(s) [2]:
ERBB2
NCIT ID [1]:
C173076

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.